C(21)-fluorinated thevinol scaffold for opioid ligands. 21,21,21-Trifluoro-6-O-nororvinols: Design, synthesis and analgesic activity
- PMID: 36966650
- DOI: 10.1016/j.ejmech.2023.115296
C(21)-fluorinated thevinol scaffold for opioid ligands. 21,21,21-Trifluoro-6-O-nororvinols: Design, synthesis and analgesic activity
Abstract
Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR mediated antinociception and OR antagonism. Herein, we disclose for the first time the OR activity of orvinols fluorinated within the pharmocophore associated with C(20) and its surrounding along with a dependence of the activity profile on the substituent at N(17). Starting from thevinone and 18,19-dihydrothevinone, a family of C(21)-fluorinated orvinols bearing methyl, cyclopropylmethyl (CPM), and allyl substituent at N(17) was synthesized. The fluorinated compounds were evaluated for OR activity. The orvinols bearing three fluorine atoms at C(21) were found to retain the properties of OR ligands and their activity profile depends on the substituent at N(17). Pilot in vivo experiments in a model of acute pain (tail-flick test in mice) revealed that 6-O-desmethyl-21,21,21-trifluoro-20-methylorvinol at doses 1.0-10.0 mg/kg (s.c.) exhibits analgesic activity at the level of morphine for a duration of 30-180 min. Its N(17)-CPM counterpart demonstrated the partial opioid agonist properties. The N(17)-allyl substituted derivative showed no analgesic activity. In vivo evaluation of an analgesic activity indicates that 21,21,21-trifluoro-20-methylorvinols represent a novel family of OR ligands related to buprenorphine, diprenorphine, etc. These compounds are promising for the structure-activity relationship studies among the thevinol/orvinol series as well as for a search for new OR ligands with potentially valuable pharmacological profiles.
Keywords: Analgesic activity; Fluorinated opioid ligands; Orvinols; Pharmacophore; Thevinols.
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore.Eur J Med Chem. 2024 Dec 18;284:117189. doi: 10.1016/j.ejmech.2024.117189. Online ahead of print. Eur J Med Chem. 2024. PMID: 39721289
-
C(21)-Di- and monofluorinated scaffold for thevinol/orvinol-based opioid receptor ligands.Org Biomol Chem. 2023 Nov 22;21(45):9091-9100. doi: 10.1039/d3ob01577g. Org Biomol Chem. 2023. PMID: 37947030
-
Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.ACS Chem Neurosci. 2013 Sep 18;4(9):1256-66. doi: 10.1021/cn4000428. Epub 2013 Jun 11. ACS Chem Neurosci. 2013. PMID: 23713721 Free PMC article.
-
The orvinols and related opioids--high affinity ligands with diverse efficacy profiles.Curr Pharm Des. 2004;10(7):717-32. doi: 10.2174/1381612043453027. Curr Pharm Des. 2004. PMID: 15032698 Review.
-
Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations.Molecules. 2022 Apr 30;27(9):2863. doi: 10.3390/molecules27092863. Molecules. 2022. PMID: 35566212 Free PMC article. Review.
Cited by
-
Monofluoromethylation of N-Heterocyclic Compounds.Int J Mol Sci. 2023 Dec 18;24(24):17593. doi: 10.3390/ijms242417593. Int J Mol Sci. 2023. PMID: 38139426 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources